1-6 of 6
Susan B. Panozzo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2128.
https://doi.org/10.1182/blood.V124.21.2128.2128
Published: 2014
Journal Articles

Final Results Of Phase II Study Of Pomalidomide (Pom) In GEP-Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Saad Z Usmani, MD, FACP, Kelly Stratton, Emily Hansen, MS, Qing Zhang, PhD, Susan B. Panozzo, BS, Nathan M Petty, MS, Antje Hoering, Sarah Waheed, MD, Frits van Rhee, John Crowley, PhD, Bart Barlogie, MD
Journal: Blood
Blood (2013) 122 (21): 3191.
https://doi.org/10.1182/blood.V122.21.3191.3191
Published: 2013
Journal Articles

Impact Of Elotuzumab Therapy On Circulating and Ex Vivo Activated/Expanded Autologous Natural Killer (Auto-ENK) Cell Activity

Susann Szmania, BS, Amy D Greenway, BS, Joshuah D Lingo, BS, Katie Stone, BS, Junaid Khan, PhD, Tarun K. Garg, PhD, Nathan M Petty, MS, Susan B. Panozzo, BS, Emily Woods, BS, Jessica Warden, Joshua Epstein, DSc, Bart Barlogie, MD, PhD, Frits van Rhee, MD,PhD
Journal: Blood
Blood (2013) 122 (21): 5389.
https://doi.org/10.1182/blood.V122.21.5389.5389
Published: 2013
Journal Articles

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Christoph Heuck, MD, Frits van Rhee, MD, PhD, Alan Mitchell, Adam Rosenthal, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Ryan Williams, Ryan van Laar, PhD, Susan B. Panozzo, BS, Jeffrey Sawyer, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 126.
https://doi.org/10.1182/blood.V122.21.126.126
Published: 2013
Journal Articles

Phase II Study of Pomalidomide (Pom) in Genomically Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Saad Z Usmani, MD, FACP, Emily Hansen, MS, Doug Steward, Sarah Waheed, MD, Susan B. Panozzo, Nathan M Petty, Shebli Atrash, MD, Al-Ola Abdallah, MD, Nisar Ahmad, MD, Antje Hoering, John Crowley, PhD, Bart Barlogie, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4083.
https://doi.org/10.1182/blood.V120.21.4083.4083
Published: 2012
Journal Articles

Pharmacogenomic Study of Carfilzomib in Relapsed/Refractory Multiple Myeloma Suggests That Carfilzomib Is a More Potent Proteasome Inhibitor Than Bortezomib

Qing Zhang, PhD, Christoph Heuck, MD, Ya-Wei Qiang, MD, PhD, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Clyde Bailey, Susan B. Panozzo, Joshua Epstein, DSc, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP
Journal: Blood
Blood (2012) 120 (21): 5015.
https://doi.org/10.1182/blood.V120.21.5015.5015
Published: 2012